Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating expenses:
Research and development	$ 297	$ 480
General and administrative	100,803	166,742
Total operating expenses	101,100	167,222
Loss from operations	(101,100)	(167,222)
Other income (expense):
Interest expense, net	(203,797)	(234,709)
Reimbursement for expenses - related party		12,538
Change in fair value of derivative on debt	(59,367)	2,476
Loss on extinguishment / conversion of debt		(88,258)
Total other expense	(263,164)	(307,953)
Net loss before non-controlling interests	(364,264)	(475,175)
Net loss attributable to non-controlling interests	(65,548)	(66,499)
Net loss attributable to Oncotelic Therapeutics, Inc.	$ (298,716)	$ (408,676)
Basic net loss per share attributable to common stock	$ (0.00)	$ (0.00)
Diluted net loss per share attributable to common stock	$ (0.00)	$ (0.00)
Basic weighted average common stock outstanding	407,423,329	399,378,572
Diluted weighted average common stock outstanding	407,423,329	399,378,572